A Phase 2 interventional study of Carfilzomib in Multiple Myeloma and Solid Tumors, sponsored by Amgen. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-14.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 27th largest by enrollment, is one of 2 that started in 2009, is one of 50 in phase 2, and was the 7th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 20th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 2, and was the 11th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
Drug: Carfilzomib
Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
Also known as: PR-171, PR171, Kyprolis®
Number of Participants With Peripheral Neuropathy
Participants with peripheral neuropathy or peripheral neuropathy-related adverse events, including hypoaesthesia, paraesthesia, dysaesthesia, and neuropathic pain.
Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Number of Participants With Adverse Events
Adverse events (AEs) were assigned a severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 3.0. Per protocol, adverse events were collected if they led to dose modification or dose discontinuation, were grade ≥ 3 or serious, or were events of peripheral neuropathy (any grade). A serious AE is one that met one or more of the following criteria: * Death * Life threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect in the offspring of an exposed subject * Important medical events that, based upon appropriate medical judgment, jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes above.
Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Overall Survival
Since participants were only followed up to 30 days after administration of last dose of study drug per protocol, Kaplan-Meier estimates of overall survival were not calculated. The number of participants who died within 30 days after administration of last dose of study drug is reported.
Time frame: From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Progression-free Survival
Progression-free survival (PFS) was defined as the time between the start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurred first. Disease progression was determined by the local investigator for regimens with the same baseline using the International Uniform Response Criteria (IMWG-URC) for participants with multiple myeloma and Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumor participants. PFS was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.
Time frame: From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
Time to Progression
Time to progression (TTP) was defined as the time between start of treatment to the first documentation of disease progression. TTP was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.
Time frame: From first dose of study drug in study PX-171-010 to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.
This study was conducted at 23 centers in the United States and Canada from April 2009 to May 2017.
| Milestone | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Started | 9 | 92 |
| Received treatment | 9 | 91 |
| Completed | 7 | 67 |
| Not completed | 2 | 25 |
| Withdrew: Non-fatal progressive disease | 0 | 8 |
| Withdrew: Fatal progressive disease | 0 | 1 |
| Withdrew: Non-fatal adverse event | 1 | 0 |
| Withdrew: Fatal adverse event | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 6 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Other | 0 | 4 |
| Withdrew: Did not receive study drug | 0 | 1 |
Participants with peripheral neuropathy or peripheral neuropathy-related adverse events, including hypoaesthesia, paraesthesia, dysaesthesia, and neuropathic pain.
| participants | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Number of Participants With Peripheral Neuropathy | 1 | 15 |
Adverse events (AEs) were assigned a severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 3.0. Per protocol, adverse events were collected if they led to dose modification or dose discontinuation, were grade ≥ 3 or serious, or were events of peripheral neuropathy (any grade). A serious AE is one that met one or more of the following criteria: * Death * Life threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect in the offspring of an exposed subject * Important medical events that, based upon appropriate medical judgment, jeopardized the participant and may have required medical or surgical intervention to prevent one of the outcomes above.
| participants | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Any adverse event | 7 | 84 |
| Adverse event ≥ grade 3 | 5 | 66 |
| Serious adverse events | 5 | 57 |
| Fatal adverse events | 1 | 7 |
| AE leading to discontinuation of carfilzomib | 5 | 20 |
Since participants were only followed up to 30 days after administration of last dose of study drug per protocol, Kaplan-Meier estimates of overall survival were not calculated. The number of participants who died within 30 days after administration of last dose of study drug is reported.
| participants | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Overall Survival | 1 | 7 |
Progression-free survival (PFS) was defined as the time between the start of treatment and first evidence of documented disease progression or death (due to any cause), whichever occurred first. Disease progression was determined by the local investigator for regimens with the same baseline using the International Uniform Response Criteria (IMWG-URC) for participants with multiple myeloma and Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumor participants. PFS was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.
| months | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Progression-free Survival | 41.9 (NA to NA) | 19.6 (10.2 to 30.6) |
Time to progression (TTP) was defined as the time between start of treatment to the first documentation of disease progression. TTP was re-calculated whenever the baseline was reset due to addition of new anti-cancer therapy or increase of carfilzomib dose/frequency.
| months | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Time to Progression | NA (NA to NA) | 19.6 (10.2 to 30.6) |
Collected over From first dose of study drug to 30 days after the last dose; median duration of treatment was 14 weeks for participants with solid tumors and 44 weeks for participants with multiple myeloma.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Solid Tumors | 1/9 (11.1%) | 5/9 (55.6%) | 6/9 (66.7%) |
| Multiple Myeloma | 7/91 (7.7%) | 57/91 (62.6%) | 69/91 (75.8%) |
| Event | Solid Tumors | Multiple Myeloma |
|---|---|---|
| Cardiac tamponadeCardiac disorders | 1/9 | 0/91 |
| CardiomyopathyCardiac disorders | 1/9 | 0/91 |
| Herpes zoster ophthalmicInfections and infestations | 1/9 | 0/91 |
| InfectionInfections and infestations | 1/9 | 0/91 |
| PneumoniaInfections and infestations | 1/9 | 10/91 |
| SepsisInfections and infestations | 1/9 | 3/91 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/9 | 1/91 |
| Renal failure acuteRenal and urinary disorders | 1/9 | 4/91 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 1/9 | 0/91 |
| InfluenzaInfections and infestations | 0/9 | 6/91 |
| Event | Solid Tumors | Multiple Myeloma |
|---|---|---|
| VomitingGastrointestinal disorders | 3/9 | 5/91 |
| FatigueGeneral disorders | 3/9 | 16/91 |
| Upper respiratory tract infectionInfections and infestations | 1/9 | 21/91 |
| NauseaGastrointestinal disorders | 2/9 | 11/91 |
| PyrexiaGeneral disorders | 2/9 | 4/91 |
| NasopharyngitisInfections and infestations | 2/9 | 1/91 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/9 | 14/91 |
| NeutropeniaBlood and lymphatic system disorders | 0/9 | 19/91 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 18/91 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/9 | 16/91 |
All participants who received at least 1 dose of carfilzomib after enrollment in PX-171-010.
| Age, Continuous(years) | Solid Tumors | Multiple Myeloma | Total |
|---|---|---|---|
| Mean | 61.2 ± 12.75 | 63.2 ± 9.82 | 63.0 ± 10.05 |
| Age, Customized(Participants) | Solid Tumors | Multiple Myeloma | Total |
|---|---|---|---|
| < 65 years | 5 | 47 | 52 |
| ≥ 65 years | 4 | 44 | 48 |
| Sex: Female, Male(Participants) | Solid Tumors | Multiple Myeloma | Total |
|---|---|---|---|
| Female | 6 | 38 | 44 |
| Male | 3 | 53 | 56 |
| Race/Ethnicity, Customized(Participants) | Solid Tumors | Multiple Myeloma | Total |
|---|---|---|---|
| White | 9 | 71 | 80 |
| Black | 0 | 11 | 11 |
| Hispanic | 0 | 5 | 5 |
| Asian/Pacific Islander | 0 | 4 | 4 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Solid Tumors | Multiple Myeloma | Total |
|---|---|---|---|
| 0 (Fully active) | 6 | 39 | 45 |
| 1 (Restricted but ambulatory) | 3 | 42 | 45 |
| 2 (Ambulatory but unable to work) | 0 | 10 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2009 to primary completion in May 2017, 97 months.
Results were first posted in May 2018, 11 months after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 97 months is above that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib